Methods of treatment using exendin peptides or GLP-1 peptides
First Claim
1. A method for treating renal failure, hypertension, congestive heart failure, nephrotic syndrome, pulmonary edema, systemic edema, or cirrhosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of (i) an exendin peptide having at least 90% sequence identity to the exendin-4 peptide comprising the amino acid sequence of SEQ ID NO. 2, or (ii) a GLP-1 peptide having at least 90% sequence identity to the GLP-1 peptide comprising the amino acid sequence of SEQ ID NO. 3.
3 Assignments
0 Petitions
Accused Products
Abstract
Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
67 Citations
45 Claims
- 1. A method for treating renal failure, hypertension, congestive heart failure, nephrotic syndrome, pulmonary edema, systemic edema, or cirrhosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of (i) an exendin peptide having at least 90% sequence identity to the exendin-4 peptide comprising the amino acid sequence of SEQ ID NO. 2, or (ii) a GLP-1 peptide having at least 90% sequence identity to the GLP-1 peptide comprising the amino acid sequence of SEQ ID NO. 3.
- 7. A method for treating renal failure, hypertension, congestive heart failure, nephrotic syndrome, pulmonary edema, systemic edema, or cirrhosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of (i) an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO. 2, or (ii) a GLP-1 peptide comprising the amino acid sequence of SEQ ID NO. 3.
- 13. A method for treating renal failure, hypertension, congestive heart failure, nephrotic syndrome, pulmonary edema, systemic edema, or cirrhosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of (i) an exendin peptide having at least 95% sequence identity to the exendin-4 peptide comprising the amino acid sequence of SEQ ID NO. 2, or (ii) a GLP-1 peptide having at least 95% sequence identity to the GLP-1 peptide comprising the amino acid sequence of SEQ ID NO. 3.
Specification